Sign in
CompletedPhase 4

Immunogenicity of Influenza Vaccinations

Key facts

Who runs it
Duke University
Where
Atlanta, Cleveland, Phoenix, Pittsburgh, St Louis, and Tempe, United StatesSee the 7 sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
606 people enrolled
Started
9 Sept 2024
Ended
4 Jun 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Flucelvax® (ccIIV3)
  • Flublok® (RIV3)
Record updated
28 July 2026

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Adults aged 18-64 years that have not received the current season's influenza vaccine
  • English literate
  • Email or text message capability for weekly follow-up
  • Intention of receiving influenza vaccine based on ACIP-CDC guidelines
  • Willing to provide written/electronic informed consent
  • Intention of being available for entire study period and able to complete all relevant study procedures, including follow-up phone calls and clinic visits

Who cannot take part

  • Receipt of the current season's influenza vaccine (receipt after July 1, 2024)
  • History of severe allergic reaction after a previous dose of any influenza vaccine or to an influenza vaccine component
  • Receipt of any licensed or investigational live vaccine within 6 weeks or non-live vaccine within 2 weeks prior to enrollment in this study or planning receipt of any vaccines between visits 1 and 2 of the study (approximately within 4 weeks after the receipt of study-administered vaccine)
  • History of febrile illness (> 100.0°F or 37.8°C) within the past 72 hours prior to vaccine administration
  • History of Guillain-Barré syndrome
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
  • Any condition which, in the opinion of the investigators, may pose a health risk to the participant or interfere with the evaluation of the study objectives; Temporary Delay Criteria (Visit 1)
  • Currently pregnant, planning to become pregnant within the first three months of the study per participant self-report

Where in United States

  • Centers for Disease Control and PreventionAtlanta, United States
  • University Hospitals Cleveland Medical Center*Cleveland, United States
  • VA Northeast Ohio Healthcare System (VANEOHS)Cleveland, United States
  • Valleywise Health Comprehensive Health CenterPhoenix, United States
  • Department of Family Medicine, University of Pittsburgh School of MedicinePittsburgh, United States
  • Washington University IDCRUSt Louis, United States
  • ASU Biodesign InstituteTempe, United States

About the trial

What the trial wants to find out

This study is a randomized immunogenicity study in an enrolled cohort with active surveillance for influenza-like illness (ILI). During this study, participants will be randomly assigned to receive an approved cell culture-based influenza vaccine (Flucelvax®) versus a licensed comparator influenza vaccine (Flublok®). Blood samples from participants will be collected for measurement of biomarkers of immune response at baseline (visit 1; day 1), post-vaccination (visit 2; day 29), and post-season (visit 3; day 181). Participants will be asked if they wish to also provide saliva specimens at baseline (visit 1; day 1), post-vaccination (visit 2; day 29), and post-season (visit 3; day 181). Serum and peripheral blood mononuclear cells (PBMC) and plasma samples will be isolated from whole blood and tested for biomarkers of vaccine immunogenicity, and duration of antibody responses.

Read full original descriptionShow less

Participants will receive electronic surveys via email or text message weekly asking about changes in health status and new ILI symptoms; those reporting illness may be asked to provide a respiratory swab for laboratory testing for influenza and other respiratory viruses and up to 2 additional blood draws (acute [<10 days after symptom onset] and convalescent [28 days after acute visit if lab-confirmed positive for influenza]).

The 2 groups in the trial

  • Flucelvax® (ccIIV3)Treatment being tested

    Participants will receive Flucelvax® (ccIIV3) at Visit 1.

  • Flublok® (RIV3)Treatment being tested

    Participants will receive Flublok® (RIV3) at Visit 1.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Measuring Immunity Against Circulating Influenza Viruses: Randomized Immunogenicity Study Among US Adults Aged 18-64 Years Comparing Two Approved Influenza Vaccines
Publications
Record updated
28 July 2026